Key Highlights

  • The stock fell 25.05% to USD 0.6626 in pre-market trading on November 3, 2026.
  • A special stockholder meeting is scheduled for November 6, 2026 to vote on swapping about USD 2.9 million of Debt for stock.
  • A proxy filing showed that a full exchange at a USD 7.06 minimum price could mean 3,596,425 shares.
  • Reverse splits of 1-for-35 and 1-for-15 took effect on April 30, 2026 and September 17, 2026.
  • A USD 75 million mixed securities shelf was filed on October 22, 2026.

What pushed the shares lower before the open (down USD 0.2215, 25.05%)

Jaguar Health (NASDAQ:JAGX) fell 25.05% to USD 0.6626 in pre-market trading on November 3, 2026. That points to a November 2 close near USD 0.88 (calculated). No company press release dated November 2 or 3, 2026 was identified as the trigger.

Dilution pressure ahead of the November 6, 2026 meeting is a possible backdrop, although the company has not linked any price move to it.

The proposed debt exchange

A revised preliminary proxy statement said stockholders will vote on allowing the company to swap Series Q preferred stock and debt held by affiliates of a lender for common stock. The debt totals about USD 2,895,351, including a 2021 note of about USD 1,638,024 and two Royalty interests.

At an illustrative minimum price of USD 7.06, a full exchange would issue 3,596,425 shares, about 64.9% of common stock after issuance. The filing noted that only 1,945,542 shares were outstanding as of September 25, 2026, and a lower price would mean many more shares. At USD 1.00, the figure would be 25,390,851 shares.

Business background

Jaguar Health is a commercial-stage pharmaceutical company developing plant-based prescription medicines for people and animals with gastrointestinal distress. Its lead drug is Mytesi, approved for non-infectious diarrhea in adults living with HIV/AIDS.

In October 2026 the company said crofelemer showed benefit for intestinal failure in a third rare congenital enteropathy, and its affiliate Napo recapped positive preliminary short bowel syndrome results presented on October 13, 2026. For the second quarter of 2026, reported on August 19, 2026, the company disclosed Revenue of about USD 1.2 million and a net loss of about USD 12.7 million.

Dilution and Capital Structure risk

The same proxy includes a plan to reprice investor warrants to USD 1.00 per share, raise the Equity plan reserve, and approve a reverse split range of 1-for-2 to 1-for-150. Another item would lower the floor price of a June 9, 2026 equity line from USD 16.50.

In October 2026 the company also declared a special stock dividend, described as dilution protection while it evaluates strategic alternatives. As a penny stock, JAGX can be highly volatile and illiquid, and extended-hours quotes may differ from regular trading. Dilution and listing risk remain central.

What to watch next

The November 6, 2026 meeting is the next firm date, with the outcome expected in a regulatory filing. The final exchange price, any new reverse split ratio and further filings under the USD 75 million shelf would shape the share count.

Updates on the planned crofelemer drug application and third quarter results may also matter.